Clinical Trials Logo
  1. Home
  2. Platelet Reactivity
  3. NCT02808039

Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial

Platelet Reactivity Clinical Trial

Official title:
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial

Clinical Trial Summary

to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function

Clinical Trial Description

the study will be composed of a cohort of patients , who completed 12 months of DAPT with Ticagrelor (standard recommended dose for ACS - 90 mg BID), did not experience any clinical or adverse event during this time period and are about to discontinue Ticagrelor. We intend to measure the platelet reactivity for each patient on 4 time points - prior to cessation of Ticagrelor (i.e. while still on DAPT) and 1,4 and 12 weeks post discontinuation of therapy. There will not be a control group. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02808039
Study type Observational
Source Rabin Medical Center
Contact Guy Witberg, MD
Phone (+972)528478828
Email vitberguy@gmail.com
Status Not yet recruiting
Phase N/A
Start date September 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01961856 - Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor. Phase 3
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01463163 - Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT01463150 - Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Phase 4
Recruiting NCT03614832 - Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Phase 4
Completed NCT01835353 - High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT04001894 - Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease Phase 4
Recruiting NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy Phase 4
Completed NCT01511471 - Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Phase 3
Completed NCT00827346 - Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty Phase 2/Phase 3
Completed NCT00976196 - Platelet Hyperreactivity Project N/A
Recruiting NCT05367336 - Platelet Reactivity With Fentanyl, Morphine, or no Narcotic Early Phase 1
Completed NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. Phase 4
Recruiting NCT05657041 - Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Phase 2/Phase 3